Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?

Angie Garcia, Karen J. Vigil, Barbara Taylor, Onkar Kshirsagar, Mae Thamer, Mamta K. Jain

Producción científica: Articlerevisión exhaustiva

Resumen

Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.

Idioma originalEnglish (US)
Páginas (desde-hasta)790-792
Número de páginas3
PublicaciónJournal of Viral Hepatitis
Volumen30
N.º10
DOI
EstadoPublished - oct 2023

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology
  • Hepatology

Huella

Profundice en los temas de investigación de 'Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?'. En conjunto forman una huella única.

Citar esto